Premium
Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India
Author(s) -
Chauhan Sanshriti,
Meshram Hari Shankar,
Kute Vivek,
Patel Himanshu,
Desai Sudeep,
Dave Ruchir
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13735
Subject(s) - medicine , interquartile range , asymptomatic , single center , cohort , surgery
Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported. Methods We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed. Results The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%). The most common persistent symptom was fatigue which significantly decreased in the follow‐up ( n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p ‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p ‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up ( n = 4, 3% vs. 7, 5% vs. 3, 2%; p ‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline. Conclusion Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up.